Shattuck Labs Announces Participation in Upcoming March Conferences
Shattuck Labs, Inc. (STTK) announced participation in investor conferences to discuss the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. Key conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Citi's Biotech C-Suite Fireside Chat Series.
02/26/2024 - 07:00 AM
AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.
Presentation Details Conference: TD Cowen 44th Annual Health Care Conference Format: Panel Discussion and 1x1 Meetings Panel Topic: Novel IO Corporate Panel Discussion
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer Date: March 4, 2024 Time: 10:30-11:30 a.m. ET Conference: Leerink Partners Global Biopharma Conference 2024 Format: 1x1 Meetings Dates: March 11-12, 2024
Conference: Citi's Biotech C-Suite Fireside Chat Series Format: Fireside chat with covering analyst Yigal Nochomovitz, Ph.D.
Presenters: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer Date: March 20, 2024 Time: 11:00 a.m. ET A live webcast of the presentations will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com .
Investor & Media Contact: Conor Richardson Vice President of Investor Relations Shattuck Labs, Inc.InvestorRelations@shattucklabs.com
When will Shattuck Labs participate in the TD Cowen 44th Annual Health Care Conference?
Shattuck Labs will participate in the TD Cowen 44th Annual Health Care Conference on March 4, 2024.
Who will be the presenter at the Novel IO Corporate Panel Discussion?
Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will be the presenter at the Novel IO Corporate Panel Discussion.
What is the format of the Leerink Partners Global Biopharma Conference 2024?
The Leerink Partners Global Biopharma Conference 2024 will have 1x1 Meetings on March 11-12, 2024.
Who are the presenters at Citi's Biotech C-Suite Fireside Chat Series?
Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer, will be the presenters at Citi's Biotech C-Suite Fireside Chat Series.
Where can the live webcast of the presentations be accessed?
The live webcast of the presentations will be available on the Investors section of Shattuck Labs' website.
How long will the replay of the webcast be archived?
The replay of the webcast will be archived for up to 30 days following the presentation date.
STTK Rankings
#4347 Ranked by Stock Gains
STTK Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About STTK
shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex